Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.10−0.21 (-1.29%)
Close on Nov 18, 2026Market cap $895.47MP/E –Yield –
Aktis Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$34.75M | – |
| Q2 FY2026 | Jun 30, 2026 | -$28.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.14M | – |
See a number that looks wrong?